MDL | - |
---|---|
Molecular Weight | 416.57 |
Molecular Formula | C24H32O4S |
SMILES | C[C@@]12[C@](OC3=O)(CC3)CC[C@@]1([H])[C@@]([C@@H](CC4=CC5=O)SC(C)=O)([H])[C@]([C@]4(CC5)C)([H])CC2 |
Spironolactone (SC9420) is an orally active aldosterone mineralocorticoid receptor antagonist with an IC 50 of 24 nM. Spironolactone is also a potent antagonist of androgen receptor with an IC 50 of 77 nM. Spironolactone promotes autophagy in podocytes [1] [2] [3] .
NCT Number | Sponsor | Condition | Start Date | Phase |
---|---|---|---|---|
NCT00604006 | Monash University|National Heart Foundation, Australia |
Heart Failure
|
September 2008 | Phase 3 |
NCT01897727 | University of Alabama at Birmingham|National Heart, Lung, and Blood Institute (NHLBI) |
Obstructive Sleep Apnea|Resistant Hypertension|Hyperaldosteronism
|
January 2009 | Not Applicable |
NCT01195805 | Regional Hospital Holstebro |
Essential Hypertension
|
August 2010 | Not Applicable |
NCT02253394 | Brigham and Women´s Hospital|Gilead Sciences |
Pulmonary Arterial Hypertension
|
September 2015 | Phase 4 |
NCT00276289 | Indiana University School of Medicine|Indiana University |
Idiopathic Hypercalciuria|Hypokalemia Caused by Thiazide Diuretics
|
January 2006 | Not Applicable |
NCT04327232 | National University Hospital, Singapore|University of Otago |
Atrial Fibrillation
|
May 23, 2018 | Phase 2 |
NCT01083290 | Orion Corporation, Orion Pharma |
Healthy
|
April 2010 | Phase 1 |
NCT00226109 | University of Aarhus |
Cardiomyopathy, Alcoholic|Alcoholism
|
April 2004 | Phase 4 |
NCT00857909 | Regional Hospital Holstebro |
High Blood Pressure
|
January 2009 | Phase 1 |
NCT01853553 | University of Colorado, Denver|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
ADPKD
|
July 2013 | Phase 3 |
NCT03744767 | Dr Irmela MANTEL|Eye Hospital Jules Gonin |
Neovascular Age-related Macular Degeneration
|
September 19, 2014 | Phase 2 |
NCT03929718 | Piedmont Healthcare |
AFib
|
April 24, 2019 | Early Phase 1 |
NCT00709137 | VA Salt Lake City Health Care System |
Hypertension
|
October 2008 | Not Applicable |
NCT02502981 | University Hospital Birmingham|Royal Free Hospital NHS Foundation Trust|University of Edinburgh|University of Cambridge |
Renal Insufficiency, Chronic|Cardio-Renal Syndrome
|
June 2014 | Phase 4 |
NCT00865501 | University of Erlangen-Nürnberg Medical School |
Primary Hypertension
|
March 2008 | Phase 3 |
NCT00211081 | Emory University |
Congenital Disorders
|
November 2004 | Not Applicable |
NCT02901184 | Uppsala University|Karolinska University|Duke Clinical Research Institute|National Heart, Lung, and Blood Institute (NHLBI) |
Heart Failure With Preserved Ejection Fraction
|
November 23, 2017 | Phase 3 |
NCT02354352 | Ohio State University|University of California, Los Angeles|University of Utah|University of Colorado, Denver|University of Kansas Medical Center|Vanderbilt University Medical Center |
Duchenne Muscular Dystrophy
|
March 20, 2015 | Phase 3 |
NCT01314898 | Pfizer |
Healthy Volunteers
|
March 2011 | Phase 1 |
NCT00664222 | Tottori University Hospital |
Chronic Stable Heart Failure
|
January 2004 | Phase 4 |
NCT00865124 | Brigham and Women´s Hospital|National Institutes of Health (NIH)|National Heart, Lung, and Blood Institute (NHLBI) |
Type 2 Diabetes Mellitus|Vascular Disease
|
September 2008 | Not Applicable |
NCT04465123 | Chiang Mai University |
Acute Heart Failure|Acute Kidney Injury
|
August 13, 2020 | Phase 3 |
NCT00317954 | Steno Diabetes Center Copenhagen |
Diabetic Nephropathy
|
September 2003 | Phase 4 |
NCT03682497 | AstraZeneca |
Heart Failure
|
November 1, 2018 | Phase 1 |
NCT03068910 | University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Hyperandrogenism|Polycystic Ovary Syndrome|Puberty
|
July 21, 2016 | Early Phase 1 |
NCT00206232 | Baylor College of Medicine |
Heart Failure
|
July 2004 | Phase 4 |
NCT02429388 | The University of Texas Health Science Center at San Antonio |
Heart Failure
|
May 2014 | Phase 4 |
NCT03291145 | Herlev and Gentofte Hospital |
Long Qt Syndrome 1-2|Sudden Cardiac Death
|
June 27, 2017 | Not Applicable |
NCT02483195 | University of Florida |
Female Androgenetic Alopecia
|
August 2016 | Phase 4 |
NCT03551548 | University Hospital, Caen|Ministry of Health, France |
Cardiac Surgery|Atrial Fibrillation|Aldosterone Blockade
|
February 26, 2019 | Phase 3 |
NCT00381134 | National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Diabetes|Kidney Disease|Hypertension
|
July 2003 | Phase 2 |
NCT01691053 | Wuerzburg University Hospital|German Federal Ministry of Education and Research|Clinical Trial Center Wuerzburg (CTCW) |
End Stage Renal Disease + Hemodialysis
|
December 2012 | Phase 2 |
NCT04826822 | Chita State Regional Clinical Hospital Number 1 |
Coronavirus Infection|Pneumonia, Viral
|
February 24, 2021 | Phase 3 |
NCT01371747 | Relypsa, Inc.|Vifor Pharma |
Chronic Kidney Disease|Hypertension|Hyperkalemia
|
June 2011 | Phase 2 |
NCT03984591 | Bispebjerg Hospital|Rigshospitalet, Denmark |
Systolic Heart Failure
|
November 1, 2020 | Phase 4 |
NCT01198496 | Biomedis International Ltd. |
Hypertension|Stroke|Blood Pressure
|
October 2010 | Phase 4 |
NCT04853355 | Wake Forest University Health Sciences |
Diabetic Maculopathy
|
July 2022 | Phase 4 |
NCT03174288 | University of Virginia|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) |
Type 1 Diabetes
|
August 2015 | Not Applicable |
NCT03048825 | Population Health Research Institute|Canadian Institutes of Health Research (CIHR)|Boston Scientific Corporation |
ST Elevation Myocardial Infarction|Non ST Elevation Myocardial Infarction
|
February 1, 2018 | Phase 3 |
NCT02053974 | TC Erciyes University |
Anthracycline Induced Cardiotoxicity
|
September 2011 | Phase 4 |
NCT02823626 | The University of Texas Health Science Center at San Antonio|Relypsa, Inc. |
Acute Decompensated Heart Failure
|
September 2016 | |
NCT05010707 | Washington University School of Medicine |
Transgenderism
|
August 2, 2021 | Phase 3 |
NCT00811486 | University of Colorado, Denver |
Right Heart Failure|Pulmonary Hypertension
|
January 2009 | Not Applicable |
NCT01867294 | Academic and Community Cancer Research United|National Cancer Institute (NCI) |
Advanced Malignant Neoplasm|Dermatologic Complication
|
August 31, 2012 | Phase 2 |
NCT01388088 | Erling Bjerregaard Pedersen|Regional Hospital Holstebro |
Hypertension
|
September 2010 | Phase 4 |
NCT00663195 | Tottori University Hospital |
Chronic Stable Heart Failure
|
January 2004 | Phase 4 |
NCT00773084 | Texas Tech University Health Sciences Center |
Diastolic Heart Failure
|
September 2008 | Not Applicable |
NCT01552044 | Institut National de la Santé Et de la Recherche Médicale, France |
Central Serous Chorioretinitis
|
January 2012 | Phase 1|Phase 2 |
NCT01843309 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
Patients With Fungic Infections
|
May 2013 | Phase 4 |
NCT01602861 | Odense University Hospital|Fredericia Hosptial |
Disorder Related to Renal Transplantation
|
February 2013 | Phase 4 |
NCT00498537 | US Department of Veterans Affairs|VA Office of Research and Development |
Diabetic Nephropathy
|
January 2003 | Not Applicable |
NCT00328809 | State University of New York - Upstate Medical University |
End Stage Renal Disease|Congestive Heart Failure
|
June 30, 2013 | Phase 4 |
NCT00335413 | Steno Diabetes Center Copenhagen |
Hypertension
|
June 2006 | Phase 4 |
NCT00429897 | University of Cambridge|British Heart Foundation |
Low-Renin Hypertension
|
August 2006 | Not Applicable |
NCT00292162 | NHS Greater Glasgow and Clyde |
Chronic Heart Failure|Atrial Fibrillation
|
January 2007 | Not Applicable |
NCT01721655 | West Virginia University Healthcare |
Chronic Lung Disease|Bronchopulmonary Dysplasia
|
October 2012 | Phase 2|Phase 3 |
NCT01103245 | Vanderbilt University Medical Center |
Metabolic Diseases|Diabetes Mellitus|Endocrine System Diseases|Glucose Metabolism Disorders
|
March 2010 | Phase 1 |
NCT04582383 | University of Pennsylvania |
Acne
|
March 30, 2022 | Phase 4 |
NCT00001202 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC) |
Precocious Puberty
|
January 1985 | Phase 2 |
NCT00125437 | Hebei Medical University |
Heart Failure, Congestive
|
September 2005 | Not Applicable |
NCT02236520 | Vanderbilt University|American Heart Association|Vanderbilt University Medical Center |
Hypertension
|
September 2014 | Phase 2 |
NCT04760717 | Yale University|American Heart Association |
Intracerebral Hemorrhage|Spironolactone
|
March 19, 2021 | Phase 2 |
NCT05394142 | Fundació Sant Joan de Déu |
Polycystic Ovary Syndrome (PCOS)
|
May 24, 2022 | Phase 2 |
NCT03344159 | Ottawa Heart Institute Research Corporation |
Chronic Right-Sided Heart Failure|Pulmonary Arterial Hypertension|Pulmonary Hypertension, Primary, 2|Pulmonary Hypertension, Primary, 3|Pulmonary Hypertension, Primary, 4|Cardiomyopathy Right Ventricular
|
April 1, 2018 | Phase 4 |
NCT04727073 | Charite University, Berlin, Germany|Deutsches Zentrum für Herz-Kreislauf-Forschung (DZHK)|Echo Core Lab Berlin|University of Göttingen|University Medicine Greifswald|Ludwig-Maximilians - University of Munich|Institute for Cardiovascular Computer-assisted Medicine, Charité|Coordinating Centre for Clinical Trials, Charité |
Heart Failure With Mid-range Ejection Fraction|Heart Failure With Preserved Ejection Fraction
|
November 1, 2018 | Phase 3 |
NCT01488877 | Pfizer |
Type 2 Diabetic Nephropathy
|
January 2012 | Phase 1 |
NCT00123955 | Wake Forest University|National Institute on Aging (NIA)|Wake Forest University Health Sciences |
Diastolic Heart Failure|Heart Failure, Congestive
|
April 2005 | Phase 3 |
NCT02417896 | Instituto Nacional de Cardiologia Ignacio Chavez|Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran |
Acute Kidney Injuries|Kidney Injuries, Acute|Kidney Injury, Acute|Acute Renal Injury|Acute Renal Injuries
|
April 2013 | Not Applicable |
NCT05230901 | University Medical Center Goettingen |
Aortic Stenosis, Severe
|
February 23, 2022 | Phase 3 |
NCT02575963 | Actinium Pharmaceuticals |
AML
|
October 2012 | Phase 1|Phase 2 |
NCT01062763 | Ib Abildgaard Jacobsen|Odense University Hospital |
Arterial Hypertension|Hypertension, Resistant to Conventional Therapy|Diabetes Mellitus
|
March 2010 | Phase 3 |
NCT00094302 | HealthCore-NERI|National Heart, Lung, and Blood Institute (NHLBI) |
Cardiovascular Diseases|Heart Diseases|Heart Failure, Congestive
|
August 2006 | Phase 3 |
NCT03071263 | Relypsa, Inc.|Vifor Pharma |
Hyperkalemia|Resistant Hypertension
|
January 23, 2017 | Phase 2 |
NCT02497300 | University of Alabama at Birmingham|National Institutes of Health (NIH) |
Chronic Kidney Disease|Albuminuria
|
March 2015 | Phase 2 |
NCT01407471 | Assistance Publique - Hôpitaux de Paris|Société de Dermatologie Française |
Cutaneous Atrophy Due to Corticosteroids
|
September 2011 | Phase 2 |
NCT04676646 | AstraZeneca |
Hyperkalaemia|Heart Failure With Reduced Ejection Fraction
|
March 8, 2021 | Phase 4 |
NCT00430794 | Sheffield Teaching Hospitals NHS Foundation Trust|University of Sheffield |
Hypertension
|
March 2007 | Phase 2 |
NCT02764619 | Svendborg Hospital|Region of Southern Denmark|Takeda |
Atrial Fibrillation
|
December 2013 | Phase 3 |
NCT01294319 | Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)|National Institutes of Health Clinical Center (CC) |
Cortisol Resistance|Negative Feedback|ACTH|Mineralcorticoid|Glucocorticoid
|
January 24, 2011 | Phase 2 |
NCT03626506 | Peking University Third Hospital|University of Michigan|Peking University |
Hypertension
|
February 13, 2019 | Not Applicable |
NCT02883400 | Wake Forest University Health Sciences |
Transplant, Liver
|
December 2014 | Phase 4 |
NCT02369081 | University of Cambridge|British Heart Foundation |
Hypertension, Resistant to Conventional Therapy
|
May 2009 | Phase 4 |
NCT03593317 | Hospices Civils de Lyon |
Arrhythmogenic Right Ventricular Dysplasia
|
September 2022 | Phase 2 |
NCT00188045 | University Hospital, Angers |
Alcoholic Cirrhosis
|
April 1995 | Phase 4 |
NCT02378805 | University Hospital Goettingen|Society for Pediatric Nephrology (Germany)|Deutsche Gesellschaft für Nephrologie|Alport Selbsthilfe e.V.|Association pour l´Information et la Recherche sur les Maladies Rénales Génétiques (AIRG)|KfH Foundation Preventive Medicine |
Alport Syndrome|Hereditary Kidney Disease|Pediatric Kidney Disease|Thin Basement Membrane Disease|Familial Benign Hematuria
|
July 1995 | |
NCT00004311 | National Center for Research Resources (NCRR)|Baylor College of Medicine|Office of Rare Diseases (ORD) |
Acanthosis Nigricans|Polycystic Ovary Syndrome
|
July 1989 | Phase 2 |
NCT00870402 | Universidad de los Andes, Chile |
Diabetic Nephropathy
|
March 2009 | Phase 4 |
NCT02285920 | University of Pennsylvania|Brigham and Women´s Hospital|George Washington University|Vanderbilt University|University of Washington |
End-Stage Renal Disease
|
November 2014 | Phase 2 |
NCT03953209 | Medical University of South Carolina |
Melasma
|
March 5, 2020 | Phase 1 |
NCT02040441 | Peter Rossing|Mosaiques Diagnostics GmbH|University Medical Center Groningen|University of Glasgow|Istituto Di Ricerche Farmacologiche Mario Negri|Univerzita Karlova v Praze|Geniko Nosokomeio Athinas Ippokrateio|Institut Klinické a Experimentální Mediciny Praze|Instituto de Investigación Sanitaria de la Fundación Jiménez Díaz|Klinikum St. Georg Leipzig|Cyril and Methodius University in Skopje|Hannover Clinical Trial Center|European Commission|Diabetes Vascular Research Foundation Hoogeveen|Universitair Ziekenhuis Gent|Universitätsklinikum Carl Gustav Carus an der Technischen Universität Dresden|Stichting VUMC|Diabetologen Hessen|Steno Diabetes Center Copenhagen |
Diabetic Nephropathy|Diabetic Retinopathy
|
March 2014 | Phase 2|Phase 3 |
NCT04075149 | University of Virginia|Waterloo Foundation |
Polycystic Ovary Syndrome|Puberty Disorders|Ovulation Disorder
|
December 18, 2019 | Early Phase 1 |
NCT01973335 | Hasselt University|Ziekenhuis Oost-Limburg|Universitaire Ziekenhuizen KU Leuven |
Heart Failure
|
November 2013 | Phase 4 |
NCT01687699 | Dialysis Outcomes Heart Failure Aldactone Study Group |
End-stage Renal Failure
|
April 2008 | Phase 4 |
NCT00175617 | University of British Columbia |
Female Pattern Hair Loss
|
September 2005 | Phase 2 |
NCT02235077 | Duke University|National Heart, Lung, and Blood Institute (NHLBI) |
Heart Failure
|
December 30, 2014 | Phase 2 |
NCT05501080 | Second Affiliated Hospital of Nanchang University |
Primary Aldosteronism
|
September 1, 2022 | Not Applicable |
NCT00277693 | Universidad de los Andes, Chile |
Hemodialysis
|
Phase 4 | |
NCT02299726 | Indiana University|National Heart, Lung, and Blood Institute (NHLBI)|Vanderbilt University|Wayne State University |
Acute Heart Failure
|
May 2015 | Phase 2 |
NCT00141778 | Vanderbilt University|National Heart, Lung, and Blood Institute (NHLBI) |
Atrial Fibrillation
|
April 2005 | Phase 2|Phase 3 |
NCT00574119 | Vanderbilt University|Vanderbilt University Medical Center |
Heart Failure|Nonischemic Dilated Cardiomyopathy
|
December 2007 | Phase 4 |
NCT03020303 | Population Health Research Institute|Canadian Institutes of Health Research (CIHR) |
Endstage Renal Disease
|
July 7, 2017 | Phase 3 |
NCT04367051 | Asan Medical Center |
Heart Failure
|
August 13, 2020 | Not Applicable |
NCT04345887 | Istanbul University-Cerrahpasa |
Respiratory Distress Syndrome, Adult
|
May 5, 2020 | |
NCT02948998 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine|Ruijin Hospital|RenJi Hospital|Shanghai Jiao Tong University Affiliated Sixth People´s Hospital |
Hypertrophic Cardiomyopathy|Fibrosis
|
May 14, 2018 | Phase 4 |
NCT04205136 | University of Michigan |
Obstructive Sleep Apnea
|
March 2022 | Phase 4 |
NCT01586442 | Montreal Heart Institute|Pfizer |
Heart Failure|Type 2 Diabetes|Glucose Intolerance
|
March 2012 | Phase 3 |
NCT02531412 | Instituto Nacional de Cancerologia de Mexico |
Critically Ill|Cancer
|
October 2015 | Phase 2|Phase 3 |
NCT00741663 | University of Padova |
Cirrhosis|Ascites
|
April 2005 | Phase 4 |
NCT01021943 | Instituto Nacional de Cardiologia Ignacio Chavez |
Kidney Transplant
|
November 2009 | Phase 2 |
NCT00865449 | Instituto Nacional de Cardiologia Ignacio Chavez |
End Stage Renal Disease
|
July 2008 | Phase 3 |
NCT04393493 | Hospital Civil de Guadalajara |
Cardiorenal Syndrome
|
July 1, 2017 | Phase 2 |
NCT01059136 | Assistance Publique - Hôpitaux de Paris |
Myocardial Infarction
|
February 2010 | Phase 3 |
NCT01089309 | Wolfson Medical Center |
Arterial Stiffness|Arterial Elasticity
|
May 2004 | Phase 4 |
NCT02907749 | Changqing Yang|Shanghai Tongji Hospital, Tongji University School of Medicine |
Cirrhosis|Portal Hypertension
|
January 1, 2018 | Phase 4 |
NCT00524615 | Jan Vaclavík|Czech Society of Hypertension|Prostejov Hospital|Brno University Hospital|Olomouc Military Hospital|Gedeon Richter Ltd.|University Hospital Olomouc |
Hypertension
|
September 2007 | Phase 4 |
NCT01848639 | University Hospital, Brest|Central Hospital, Nancy, France|Institut National de la Santé Et de la Recherche Médicale, France |
End Stage Renal Failure on Dialysis
|
June 2013 | Phase 3 |
NCT00106561 | Melbourne Health |
Kidney Disease|Diabetic Nephropathy|Glomerulonephritis|Proteinuria
|
January 2002 | Phase 2|Phase 3 |
NCT04331691 | Yonsei University |
Resistant Hypertension
|
November 16, 2020 | Phase 4 |
NCT01406015 | Brigham and Women´s Hospital |
Obesity|Insulin Resistance
|
February 2009 | Not Applicable |
NCT00353652 | University of Texas Southwestern Medical Center|National Heart, Lung, and Blood Institute (NHLBI) |
Hypertension
|
January 2005 | Phase 4 |
NCT03334682 | Nantes University Hospital |
Acne Vulgaris
|
January 31, 2018 | Phase 3 |
NCT03867682 | Actinium Pharmaceuticals |
Acute Myeloid Leukemia|Relapsed Adult AML
|
January 15, 2020 | Phase 1|Phase 2 |
NCT01598740 | Sorbent Therapeutics |
Heart Failure
|
June 2012 | Phase 1 |
NCT01069510 | Oregon Health and Science University|National Heart, Lung, and Blood Institute (NHLBI)|Oregon Clinical and Translational Research Institute |
Congenital Heart Disease|Heart Failure|Endomyocardial Fibrosis
|
February 2010 | Phase 2 |
NCT02832973 | Sao Jose do Rio Preto Medical School |
Hypertension Resistant to Conventional Therapy
|
September 2015 | Phase 4 |
NCT03597035 | University Hospitals Cleveland Medical Center|Relypsa, Inc. |
Type2 Diabetes|Hyperkalemia
|
July 17, 2018 | Phase 4 |
NCT03909529 | CMP Development, LLC |
Drug Drug Interaction
|
March 10, 2019 | Phase 1 |
NCT04424134 | Lomonosov Moscow State University Medical Research and Educational Center |
COVID 19
|
May 16, 2020 | Phase 3 |
NCT02673463 | University of Birmingham |
Atrial Fibrillation
|
January 2015 | Phase 4 |
NCT04618601 | Laikο General Hospital, Athens |
Heart Failure Acute|Heart Failure; With Decompensation
|
October 20, 2020 | Phase 4 |
NCT01468571 | Baylor College of Medicine|National Heart, Lung, and Blood Institute (NHLBI) |
Pulmonary Hypertension
|
July 2011 | Phase 4 |
NCT00240656 | Hebei Medical University |
Hypertension, Pulmonary
|
October 2005 | Phase 1 |
NCT00332904 | Hvidovre University Hospital |
Liver Cirrhosis|Portal Hypertension
|
August 2006 | Phase 4 |
NCT04522739 | Emory University|Alzheimer´s Association |
Mild Cognitive Impairment|Alzheimer Disease
|
September 6, 2022 | Phase 4 |
NCT02230891 | VA Office of Research and Development|Baylor College of Medicine |
Hypertension|Diabetes|Cardiovascular Disease
|
October 1, 2014 | Phase 2 |
NCT01855334 | Brigham and Women´s Hospital|Massachusetts General Hospital|Beth Israel Deaconess Medical Center|Joslin Diabetes Center |
End Stage Renal Disease|Hemodialysis
|
September 2013 | Phase 4 |
NCT04283656 | Thomas Jefferson University |
Transgender Health|Gender Dysphoria|Transgender Women|Human Immunodeficiency Virus
|
February 14, 2022 | Phase 1 |
NCT03314493 | Professor Fernando Figueira Integral Medicine Institute|Federal University of São Paulo |
Coronary Artery Calcification|Vascular Calcification
|
November 7, 2014 | Phase 3 |
NCT01817803 | Yonsei University |
Congestive Heart Failure
|
March 2013 | Not Applicable |
NCT02046668 | University of Dundee|Arthritis Research UK |
Osteoarthritis, Knee
|
November 2013 | Phase 4 |
NCT01712620 | National Institutes of Health Clinical Center (CC)|National Heart, Lung, and Blood Institute (NHLBI)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Pennsylvania|University of Maryland Medical Center|Medstar Health Research Institute|New England Medical Center, Tufts University School of Medicine |
Pulmonary Arterial Hypertension
|
January 10, 2014 | Phase 2 |
NCT04643691 | Assistance Publique Hopitaux De Marseille |
COVID-19|ARDS
|
September 11, 2020 | Phase 2 |
NCT03329443 | Alhasan Mujtaba Abdul-Wahid|Ministry of Health-Basra Health Directorate-Al-Sader Teaching Hospital|University of Baghdad |
Acute Kidney Injury|IHD|Contrast-induced Nephropathy
|
September 1, 2017 | Phase 2 |
NCT04901975 | Children´s Hospital of Philadelphia|National Heart, Lung, and Blood Institute (NHLBI) |
Single-ventricle
|
February 11, 2021 | Phase 1|Phase 2 |
NCT04495712 | VA Office of Research and Development |
Ventricular Arrhythmias
|
July 28, 2004 | Phase 4 |
NCT04190433 | Mayo Clinic |
Lymphoma
|
September 1, 2020 | Phase 2 |
NCT04100083 | Medical University of South Carolina |
Hidradenitis Suppurativa
|
September 21, 2020 | Phase 4 |
NCT00548912 | Dawnmarie DeFazio|West Penn Allegheny Health System |
Kidney Failure, Chronic
|
October 2007 | Phase 4 |
NCT00523757 | Justin Ezekowitz|University of Alberta |
Heart Failure
|
August 2007 | Phase 3 |
NCT03953950 | Chiang Mai University |
End Stage Renal Disease|Peritoneal Dialysis
|
October 2019 | Phase 4 |
NCT01510795 | Clinical Hospital Merkur |
Kidney Failure, Chronic
|
January 2012 | Phase 4 |
NCT02426099 | Sobngwi Eugene|University of Yaounde 1|Yaounde Central Hospital |
Hypertension, Resistant to Conventional Therapy|Diabetes Mellitus
|
October 2011 | Phase 4 |
NCT03206658 | Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran|National Council of Science and Technology, Mexico|Universidad Nacional Autonoma de Mexico |
Acute Kidney Injury
|
August 1, 2017 | Phase 3 |
NCT02194465 | Eli Lilly and Company |
Primary Hypertension
|
August 2014 | Phase 2 |
NCT00295347 | Universitätsklinikum Hamburg-Eppendorf |
Major Depression
|
December 2005 | Not Applicable |
NCT00306696 | GlaxoSmithKline |
Diabetes Mellitus
|
October 2002 | Phase 4 |
NCT00528385 | Medical University of Gdansk |
Chronic Kidney Disease|Proteinuria
|
March 2005 | Not Applicable |
NCT01526616 | University Magna Graecia |
Polycystic Ovary Syndrome
|
May 2010 | Not Applicable |
NCT00224809 | Baylor Research Institute|National Heart, Lung, and Blood Institute (NHLBI) |
Cardiovascular Diseases|Heart Diseases|Coronary Disease
|
September 2002 | Not Applicable |
NCT03777319 | Kevin Flanigan|Muscular Dystrophy Association|Nationwide Children´s Hospital |
Muscular Dystrophy, Duchenne
|
December 5, 2018 | Phase 1 |
NCT01821703 | Eli Lilly and Company |
Healthy Volunteers
|
May 2013 | Phase 1 |
NCT02585843 | Columbia University |
Heart Failure
|
November 2015 | Phase 2|Phase 3 |
NCT05092984 | University Hospital, Strasbourg, France |
Rheumatoid Arthritis
|
June 22, 2022 | Phase 3 |
NCT01345656 | Bayer |
Heart Failure
|
May 9, 2011 | Phase 2 |
NCT02689843 | Shiraz University of Medical Sciences |
Polycystic Ovary Syndrome
|
February 1, 2018 | Early Phase 1 |
NCT01128101 | UPECLIN HC FM Botucatu Unesp |
Renal Failure
|
March 2011 | Phase 4 |
NCT00291720 | University Hospital Birmingham|British Heart Foundation |
Chronic Kidney Disease|Cardiovascular Disease
|
April 2005 | Phase 2 |
NCT01130597 | Relypsa, Inc.|Vifor Pharma |
Heart Failure
|
May 2010 | Phase 2 |
NCT05561361 | Second Affiliated Hospital of Nanchang University |
Primary Aldosteronism
|
October 1, 2022 | |
NCT00860340 | University of Toledo Health Science Campus|University of Toledo |
Congestive Heart Failure
|
February 2003 | Not Applicable |
NCT04455178 | Shanghai Jiao Tong University School of Medicine |
Hypertension
|
September 23, 2020 | Phase 4 |
NCT04723862 | University of Virginia|Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) |
Hyperandrogenism|Polycystic Ovary Syndrome|Puberty
|
November 12, 2021 | Early Phase 1 |
NCT02501213 | Centre Oscar Lambret|National Cancer Institute, France |
Cancer
|
May 30, 2016 | Phase 2 |
NCT03576755 | University of California, San Francisco |
NASH - Nonalcoholic Steatohepatitis
|
January 9, 2019 | Phase 1|Phase 2 |
NCT02169089 | University Hospitals Cleveland Medical Center|University of Maryland|University of Toronto|Winthrop University |
Atherosclerosis
|
January 2016 | Phase 4 |
NCT02129621 | Central Hospital, Nancy, France |
Cardiovascular Diseases
|
May 2010 | Not Applicable |
NCT00746070 | National Taiwan University Hospital |
Aldosteronism
|
January 2007 | |
NCT01422759 | University of Virginia |
Obesity|Hyperandrogenemia|Polycystic Ovary Syndrome
|
December 9, 2016 | Not Applicable |
NCT05222191 | Indiana Institute for Medical Research |
Renal Insufficiency|Chronic Hypertension
|
February 1, 2022 | Phase 2 |
NCT01055223 | GlaxoSmithKline |
Fractures, Bone|Type II Diabetes
|
May 2009 | |
NCT03981861 | Children´s Mercy Hospital Kansas City |
PCOS
|
July 2, 2016 | Phase 2|Phase 3 |
NCT01643434 | Instituto do Coracao|Conselho Nacional de Desenvolvimento Científico e Tecnológico |
Hypertension
|
August 2012 | Phase 4 |
NCT03502031 | James A. Tumlin, MD|Nelson Kopyt, MD|NephroNet, Inc. |
Renal Insufficiency, Chronic|Diabetic Nephropathy Type 2
|
October 1, 2018 | Phase 4 |
NCT03429946 | Brigham and Women´s Hospital|Beth Israel Deaconess Medical Center|National Heart, Lung, and Blood Institute (NHLBI) |
Hypoglycemia|Healthy
|
July 17, 2013 | Phase 4 |
NCT00689598 | Taichung Veterans General Hospital |
Atrial Fibrillation
|
March 2008 | Not Applicable |
NCT00879060 | Tufts Medical Center |
Myocardial Fibrosis|Hypertrophic Cardiomyopathy
|
November 2007 | Phase 4 |
NCT00391846 | AstraZeneca |
Heart Failure|Ventricular Dysfunction, Left
|
October 2006 | Phase 4 |
NCT00842140 | University of Sao Paulo |
Polycystic Ovary Syndrome
|
February 2006 | Not Applicable |
Solid
Room temperature in continental US; may vary elsewhere.
Powder | -20°C | 3 years |
---|---|---|
4°C | 2 years | |
In solvent | -80°C | 6 months |
-20°C | 1 month |
DMSO : ≥ 50 mg/mL ( 120.03 mM )
H 2 O : 0.1 mg/mL ( 0.24 mM ; Need ultrasonic)
* "≥" means soluble, but saturation unknown.
Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
---|
1 mM | 2.4006 mL | 12.0028 mL | 24.0056 mL |
5 mM | 0.4801 mL | 2.4006 mL | 4.8011 mL |
10 mM | 0.2401 mL | 1.2003 mL | 2.4006 mL |